Bioventus Inc.

NasdaqGS:BVS Stok Raporu

Piyasa değeri: US$768.5m

Bioventus Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Bioventus kazanç ve gelirinin sırasıyla yıllık 16.9% ve 6.4% oranında artması tahmin edilirken, EPS'nin yıllık 16.1% oranında büyümesi bekleniyor.

Anahtar bilgiler

16.9%

Kazanç büyüme oranı

16.10%

EPS büyüme oranı

Medical Equipment kazanç büyümesi16.2%
Gelir büyüme oranı6.4%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme22 May 2026

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Aug 09

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...

Recent updates

Anlatı Güncellemesi • Jun 03

BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside

Analysts have maintained their $14.80 price target for Bioventus, citing slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the updated view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million, based on company guidance.
Anlatı Güncellemesi • May 19

BVS: Index Inclusion And 2026 Guidance Will Support A Higher Price

Analysts have raised their Bioventus price target from $15.00 to $16.00, citing updated assumptions related to revenue growth, profit margins, discount rates, and future P/E levels. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2026, with expected net sales of US$600 million to US$610 million and implied growth of about 6% to 7% (company guidance).
Analiz Makalesi • May 14

Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are

Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. Our analysis says...
Anlatı Güncellemesi • May 01

BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside

Analysts have maintained their Bioventus fair value estimate at $14.80 while making only small adjustments to key inputs such as the discount rate and expected future P/E, indicating fine-tuning of their valuation framework rather than a major change in outlook. What's in the News Bioventus Inc.
Anlatı Güncellemesi • Apr 17

BVS: Index Addition And 2026 Sales Guidance Will Support Further Upside

Analysts have modestly fine tuned their $14.80 price target for Bioventus, keeping it steady overall as minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions leave the valuation view essentially unchanged. What's in the News Bioventus Inc.
Anlatı Güncellemesi • Apr 03

BVS: Index Inclusion And 2026 Sales Outlook Will Support Further Upside

Analysts have revised their price target for Bioventus slightly lower from $15.00 to $14.80, reflecting updated fair value and discount rate assumptions while maintaining similar views on revenue growth, profit margin and future P/E expectations. What's in the News Bioventus Inc.
Anlatı Güncellemesi • Mar 19

BVS: 2026 Net Sales Guidance And Margin Outlook Will Support Further Upside

Analysts have adjusted their price target on Bioventus to $15.00 from $14.50, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that collectively support a slightly higher valuation. What's in the News Bioventus issued earnings guidance for 2026, setting expected net sales in a range of $600 million to $610 million.
Anlatı Güncellemesi • Mar 05

BVS: Refined Assumptions And 2026 Outlook Will Support Further Upside Potential

Analysts have adjusted their price target on Bioventus slightly lower from $15.00 to $14.50, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Bioventus issued earnings guidance for 2026, with expected net sales of $600 million to $610 million.
Anlatı Güncellemesi • Feb 19

BVS: Higher Revenue Outlook And Richer Future P/E Will Drive Upside

Analysts have revised their Bioventus price target to $13.00 from $7.00, reflecting updated views on fair value, discount rate assumptions, revenue growth expectations, profit margin outlook and future P/E multiples. Valuation Changes Fair Value: revised to $13.00 from $7.00, indicating a higher assessed equity value per share.
Anlatı Güncellemesi • Feb 05

BVS: Fine Tuned Assumptions Will Support Further Upside Potential

Analysts have nudged their price target on Bioventus to US$15.00, a modest change that reflects fine tuning to inputs such as the discount rate, long term revenue growth, profit margin assumptions, and expected future P/E rather than a shift in their overall view of the company. Valuation Changes Fair Value: Maintained at US$15.00 per share, with no change in the overall valuation output.
Anlatı Güncellemesi • Jan 22

BVS: Reaffirmed 2025 Guidance And Stable Assumptions Will Support Further Upside

Analysts have kept their fair value estimate for Bioventus unchanged at US$15.00, with only slight tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This signals a broadly steady view of the stock's risk and return profile.
Anlatı Güncellemesi • Jan 07

BVS: Reaffirmed 2025 Guidance Will Support Ongoing Upside Potential

Analysts have kept their fair value estimate for Bioventus steady at US$15.00, citing only very small tweaks to inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions that do not materially change their overall view. What's in the News Bioventus reaffirmed earnings guidance for the twelve months ending December 31, 2025, signaling no change to its previously communicated outlook.
Anlatı Güncellemesi • Dec 20

BVS: Reaffirmed 2025 Earnings Guidance Will Support Continued Upside Potential

Analysts have nudged their price target on Bioventus slightly higher to reflect modestly stronger revenue growth expectations and a marginally lower discount rate, while keeping fair value unchanged at approximately $15.00 per share. What's in the News Bioventus reaffirmed its full year 2025 earnings guidance, signaling management confidence in the current strategic and operating plan (company guidance).
Anlatı Güncellemesi • Dec 06

BVS: Earnings Guidance Will Support Continued Upside Potential In Shares

Analysts have modestly raised their price target on Bioventus to approximately $15.00 per share from about $15.00 per share, reflecting slightly lower perceived risk, stable long term growth expectations, and marginally improved profitability and valuation assumptions. What's in the News Bioventus reaffirmed its 2025 earnings guidance, projecting net sales between $560 million and $570 million.
Seeking Alpha • Dec 02

Bioventus: A New Start

Summary Bioventus is regaining stability after a volatile period, with improving margins and organic sales growth driving renewed optimism. The company trades at compelling valuation multiples—below 2x sales, ~7x adjusted EBITDA, and ~11x adjusted earnings—supported by accelerating organic revenue growth. Recent refinancing is set to reduce annual interest costs by over $2 million, and net debt has declined to $280 million, lowering leverage to around 2.5x. With continued sales and margin growth, disciplined capital allocation could enable Bioventus shares to revisit the teens by 2026. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 26

Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Anlatı Güncellemesi • Nov 22

BVS: Earnings Guidance Is Expected To Drive Share Price Higher

Analysts have updated their price target for Bioventus, raising it modestly from $14.67 to $15.00 per share. This change reflects improved revenue growth expectations, despite a slightly higher discount rate and lower projected profit margin.
Anlatı Güncellemesi • Nov 03

BVS: Net Sales Guidance Will Sustain Bullish Outlook Into 2025

Analysts have slightly raised their price target for Bioventus to $14.67 per share, citing minor updates to the company's discount rate and future price-to-earnings assumptions. What's in the News Bioventus Inc.
Anlatı Güncellemesi • Oct 20

Minimally Invasive Nonopioid Pain Management Will Expand With PNS

Analysts have modestly raised their price target for Bioventus, increasing it by $0.00 to $14.67. They cited slight adjustments to their discount rate and future price-to-earnings assumptions.
Anlatı Güncellemesi • Oct 05

Minimally Invasive Nonopioid Pain Management Will Expand With PNS

Analysts have raised their price target for Bioventus from $12.75 to approximately $14.67 per share, citing improvements in projected revenue growth and a more favorable future price-to-earnings outlook. What's in the News Bioventus issued new earnings guidance for 2025 and estimates net sales between $560 million and $570 million.
Analiz Makalesi • Aug 14

We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative

NasdaqGS:BVS 1 Year Share Price vs Fair Value Explore Bioventus's Fair Values from the Community and select yours...
Analiz Makalesi • Aug 09

Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next

It's been a pretty great week for Bioventus Inc. ( NASDAQ:BVS ) shareholders, with its shares surging 12% to US$6.92 in...
User avatar
Yeni Anlatı • May 30

Cost Effective Therapies And Regenerative Medicine Will Transform Global Markets

Accelerated adoption of minimally invasive therapies and portfolio expansion in regenerative medicine are driving higher margins and capturing increased demand from demographic trends.
Analiz Makalesi • May 07

Is Bioventus (NASDAQ:BVS) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analiz Makalesi • Mar 08

Investors Aren't Buying Bioventus Inc.'s (NASDAQ:BVS) Revenues

Bioventus Inc.'s ( NASDAQ:BVS ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...
Seeking Alpha • Jan 05

Bioventus: Amply Rewarded For Recent Progress

Summary The stock of medical device concern Bioventus has roughly doubled over the past year, but has lost momentum recently. Management has done a commendable job in recent years in reducing debt and leverage ratios, and profits have rebounded significantly. What's ahead for Bioventus in 2025? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Aug 12

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Summary Bioventus Inc. posted strong Q2 results, with revenue up 10.3% and a raised full-year sales forecast. The company focuses on orthobiologics and active healing products, with key products like DUROLANE and EXOGEN. Despite positive performance, high debt and tough competition could impact future profits and valuation. Read the full article on Seeking Alpha
Seeking Alpha • Jan 24

Bioventus: Bullish On Path To Profitability

Summary Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis. Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:BVS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2028685471081053
12/31/20276453896955
12/31/20266052984855
3/28/202657628101103N/A
12/31/2025568237275N/A
9/27/2025564105356N/A
6/28/202556423436N/A
3/29/2025568-342425N/A
12/31/2024573-363739N/A
9/28/2024555-422830N/A
6/29/2024537-44811N/A
3/30/2024523-2227N/A
12/31/2023512-97815N/A
9/30/2023503-104010N/A
7/1/2023511-169818N/A
4/1/2023514-173-110N/A
12/31/2022512-104-25-14N/A
10/1/2022517-91-15-6N/A
7/2/2022497-19-46N/A
4/2/2022466-161120N/A
12/31/2021431-5923N/A
10/2/2021399-32935N/A
7/3/202137664046N/A
4/3/202132443136N/A
12/31/2020321165572N/A
9/26/2020320167167N/A
6/27/2020316126258N/A
3/28/2020339155554N/A
12/31/20193409N/A41N/A
12/31/2018319-1N/A45N/A
4/2/2016266-23N/A25N/A
12/31/2015254-38N/A19N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BVS 'nin tahmini kazanç büyümesi (yıllık 16.9% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: BVS şirketinin kazançlarının (yıllık 16.9% ) US pazarından (yıllık 17.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BVS şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: BVS şirketinin gelirinin (yıllık 6.4% ) US pazarından (yıllık 12.5% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BVS şirketinin gelirinin (yıllık 6.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BVS 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/10 05:05
Gün Sonu Hisse Fiyatı2026/06/10 00:00
Kazançlar2026/03/28
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Bioventus Inc. 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Michael PetuskyBarrington Research Associates, Inc.
Kyle RoseCanaccord Genuity
Caitlin CroninCanaccord Genuity